DuPont de Nemours acquired Spectrum Plastics Group for Approximately $1.75 billion (net purchase price of approximately $1,781 million per FY24 10-K), a transaction completed in August 2023, structured as all cash.
Spectrum Plastics Group operates in Electronics & Industrial — Industrial Solutions, is based in United States (Atlanta, GA) and international markets. Acquired from private-equity owner AEA Investors, Spectrum Plastics Group is a leading manufacturer of critical components and devices primarily for medical end-markets requiring highly complex, mission-critical applications. Spectrum manufactures flexible packaging products, plastic and silicone extrusions, and components for the industrial, food and medical business sectors across the United States and international markets. It became part of Industrial Solutions within the Electronics & Industrial segment. The FY24 10-K records a net purchase price of approximately $1,781 million, including a net upward adjustment of approximately $43 million for acquired cash and net working capital.
This intended acquisition adds to DuPont's industrial technologies growth pillar and strengthens our existing position in stable and fast-growing healthcare end-markets. We expect this deal to add substantial shareholder value over time through both growth and clear synergies with our existing medical-related products.
Expands DuPont's exposure to stable, fast-growing medical and healthcare end-markets and complements its existing medical-related products, serving a broad base of leading medical-technology OEMs. Clear synergies with DuPont's existing medical-related products, per management commentary. Industrial Solutions within the Electronics & Industrial segment
Today we also announced a definitive agreement to acquire Spectrum Plastics Group, a leading manufacturer of critical components and devices primarily into medical end-markets for highly complex, mission critical applications. This intended acquisition adds to DuPont's industrial technologies growth pillar and strengthens our existing position in stable and fast-growing healthcare end-markets.Ed Breen, Executive Chairman and CEO, DuPont
Advisory firms were not disclosed for this transaction.